Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AlloVir, Inc.
  6. News
  7. Summary
    ALVR   US0198181036

ALLOVIR, INC.

(ALVR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALLOVIR, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

05/06/2021 | 08:39am EDT

Item 2.02 Results of Operations and Financial Condition

On May 6, 2021, AlloVir, Inc. announced its financial results for the quarter ended March 31, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1, attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



                Exhibit No.   Description

                99.1            Press release dated May 6, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ALLOVIR, INC.
05/25ALLOVIR, INC.á : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/12ADENOVIRUS INFECTIONS PIPELINE : Emerging Therapies and Key pharma players invol..
AQ
05/10INSIDER TRENDS : Alvarion Insider Extends 90-Day Selling Trend
MT
05/07ALLOVIRá : Dr. Diana Brainard's transition from independent director to CEO has ..
PU
05/06ALLOVIRá : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/06ALLOVIRá : SVB Leerink Adjusts AlloVir PT to $42 From $41, Maintains Outperform ..
MT
05/06ALLOVIR, INC.á : Results of Operations and Financial Condition, Financial Statem..
AQ
05/06ALLOVIRá : Reports First Quarter 2021 Financial Results
BU
04/19ALLOVIRá : Morgan Stanley Adjusts Price Target on AlloVir to $50 From $49, Maint..
MT
03/22ALLOVIR, INC.á : Change in Directors or Principal Officers, Regulation FD Disclo..
AQ
More news